Comparative Pharmacology
Head-to-head clinical analysis: LIDOCAINE HYDROCHLORIDE 0 8 AND DEXTROSE 5 IN PLASTIC CONTAINER versus NAROPIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIDOCAINE HYDROCHLORIDE 0 8 AND DEXTROSE 5 IN PLASTIC CONTAINER versus NAROPIN.
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER vs NAROPIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine is an amide-type local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion channels, thereby blocking the initiation and conduction of nerve impulses. It also has antiarrhythmic properties by decreasing automaticity in Purkinje fibers and suppressing ventricular arrhythmias.
Ropivacaine blocks sodium ion channels in neuronal cell membranes, inhibiting the conduction of nerve impulses.
Intrathecal administration for spinal anesthesia: 50-100 mg (1.5-2 mL of 5% solution) as a single dose. For continuous epidural or peripheral nerve block, 0.8% solution with dextrose 5% is not typically used; refer to 1-2% lidocaine without dextrose for continuous infusion.
Epidural administration: Initial dose 20-30 mL of 0.5% solution (100-150 mg) followed by 10-15 mL/hour of 0.2% solution for continuous infusion. Maximum single dose: 200 mg. Maximum daily dose: 400 mg.
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours (adults); prolonged in heart failure (up to 5-8 hours) or hepatic impairment (up to 10-15 hours). Clinically, context indicates redistribution half-life ~8 minutes.
Terminal elimination half-life: 4.2 ± 1.1 hours (adults) for ropivacaine. Clinical context: prolonged half-life in neonates (up to 12-18 hours) due to immature hepatic clearance; consider accumulation with continuous infusion in renal impairment (though minimal unchanged drug).
Renal (metabolites: 4-hydroxyxylidine, glycylxylidide, monoethylglycinexylidide; <10% unchanged). Biliary/fecal negligible.
Renal: 86-93% as metabolites (including 3-hydroxyropivacaine, 4-hydroxyropivacaine, and 2',6'-pipecoloxylidide), <1% unchanged. Biliary/fecal: <10% collectively, primarily as metabolites.
Category A/B
Category C
Local Anesthetic / Antiarrhythmic (Class Ib)
Local Anesthetic